Impleo is a medical device company, developing a minimally invasive injection therapy for Gastroesophageal Reflux Disease (GERD), the most common GI diagnosis. GERD affects >60M people in the US and many more worldwide. Our product is injected through an outpatient and cost-effective procedure.

We have completed a pilot study and started a pivotal clinical trial which, if successful, will result in FDA approval. The device has also been used in 100,000+ humans for non-GERD indication.